Skip to main content
Top
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Gene × Gene interaction between MnSOD and GPX-1 and breast cancer risk: a nested case-control study

Authors: David G Cox, Rulla M Tamimi, David J Hunter

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Germ-line mutations in genes such as BRCA1, BRCA2, and ATM can cause a substantial increase in risk of breast cancer. However, these mutations are rare in the general population, and account for little of the incidence of sporadic breast cancer in the general population. Therefore, research has been focused on examining associations between common polymorphisms and breast cancer risk. To date, few associations have been described. This has led to the hypothesis that breast cancer is a complex disease, whereby a constellation of very low penetrance alleles need to be carried to present a risk phenotype. Polymorphisms in the manganese superoxide dismutase (MnSOD) and glutathione peroxidase (GPX-1) genes have been proposed as low penetrance alleles, and have not been clearly associated with breast cancer. We investigated whether variants at both polymorphisms, while not independently associated with breast cancer risk, could influence breast cancer risk when considered together.

Methods

A case-control study nested within the Nurses' Health Study was performed comparing 1262 women diagnosed with breast cancer to 1533 disease free women. The MnSOD (Val16Ala, rs1799725) and GPX-1 (Pro198Leu, rs1050450) were genotyped via TaqMan assay. Disease risk was evaluated using logistic regression.

Results

While neither allele alone shows any change in breast cancer risk, an increase in the risk of breast cancer (OR 1.87, 95% CI 1.09 – 3.19) is observed in individuals who carry both the Ala16Ala genotype of MnSOD and the Leu198Leu genotype of GPX-1.

Conclusion

Polymorphisms in the GPX-1 and MnSOD genes are associated with an increased risk of breast cancer.
Literature
1.
go back to reference Briehl MM, Baker AF, Siemankowski LM, Morreale J: Modulation of antioxidant defenses during apoptosis. Oncol Res. 1997, 9: 281-285.PubMed Briehl MM, Baker AF, Siemankowski LM, Morreale J: Modulation of antioxidant defenses during apoptosis. Oncol Res. 1997, 9: 281-285.PubMed
2.
go back to reference Arthur JR: The glutathione peroxidases. Cell Mol Life Sci. 2000, 57: 1825-1835. 10.1007/PL00000664.CrossRefPubMed Arthur JR: The glutathione peroxidases. Cell Mol Life Sci. 2000, 57: 1825-1835. 10.1007/PL00000664.CrossRefPubMed
3.
go back to reference Hu YJ, Diamond AM: Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res. 2003, 63: 3347-3351.PubMed Hu YJ, Diamond AM: Role of glutathione peroxidase 1 in breast cancer: loss of heterozygosity and allelic differences in the response to selenium. Cancer Res. 2003, 63: 3347-3351.PubMed
4.
go back to reference Hong YC, Lee KH, Yi CH, Ha EH, Christiani DC: Genetic susceptibility of term pregnant women to oxidative damage. Toxicol Lett. 2002, 129: 255-262. 10.1016/S0378-4274(02)00014-0.CrossRefPubMed Hong YC, Lee KH, Yi CH, Ha EH, Christiani DC: Genetic susceptibility of term pregnant women to oxidative damage. Toxicol Lett. 2002, 129: 255-262. 10.1016/S0378-4274(02)00014-0.CrossRefPubMed
5.
go back to reference Tamimi RM, Hankinson SE, Campos H, Spiegelman D, Zhang S, Colditz GA, Willett WC, Hunter DJ: Plasma carotenoids, retinol, and tocopherols and risk of breast cancer. Am J Epidemiol. 2005, 161: 153-160. 10.1093/aje/kwi030.CrossRefPubMed Tamimi RM, Hankinson SE, Campos H, Spiegelman D, Zhang S, Colditz GA, Willett WC, Hunter DJ: Plasma carotenoids, retinol, and tocopherols and risk of breast cancer. Am J Epidemiol. 2005, 161: 153-160. 10.1093/aje/kwi030.CrossRefPubMed
6.
go back to reference Tamimi RM, Hankinson SE, Spiegelman D, Colditz GA, Hunter DJ: Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2004, 13: 989-996.PubMed Tamimi RM, Hankinson SE, Spiegelman D, Colditz GA, Hunter DJ: Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2004, 13: 989-996.PubMed
7.
go back to reference Cox DG, Hankinson SE, Kraft P, Hunter DJ: No association between GPX1 Pro198Leu and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2004, 13: 1821-1822.PubMed Cox DG, Hankinson SE, Kraft P, Hunter DJ: No association between GPX1 Pro198Leu and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2004, 13: 1821-1822.PubMed
8.
go back to reference De Vivo I, Hankinson SE, Colditz GA, Hunter DJ: A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res. 2003, 63: 5236-5238.PubMed De Vivo I, Hankinson SE, Colditz GA, Hunter DJ: A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res. 2003, 63: 5236-5238.PubMed
9.
go back to reference Gauderman WJ: Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med. 2002, 21: 35-50. 10.1002/sim.973.CrossRefPubMed Gauderman WJ: Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med. 2002, 21: 35-50. 10.1002/sim.973.CrossRefPubMed
Metadata
Title
Gene × Gene interaction between MnSOD and GPX-1 and breast cancer risk: a nested case-control study
Authors
David G Cox
Rulla M Tamimi
David J Hunter
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-217

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine